
    
      This study is a prospective, randomized, multi-center global investigation. Subjects will be
      randomized to either the WATCHMAN FLX Left Atrial Appendage Closure Device ("Device Group")
      or a commercially available non-vitamin K oral anticoagulant ("Control Group").
    
  